A Molecular Imaging Primer: Modalities, Imaging Agents, and Applications

2012 ◽  
Vol 92 (2) ◽  
pp. 897-965 ◽  
Author(s):  
Michelle L. James ◽  
Sanjiv S. Gambhir

Molecular imaging is revolutionizing the way we study the inner workings of the human body, diagnose diseases, approach drug design, and assess therapies. The field as a whole is making possible the visualization of complex biochemical processes involved in normal physiology and disease states, in real time, in living cells, tissues, and intact subjects. In this review, we focus specifically on molecular imaging of intact living subjects. We provide a basic primer for those who are new to molecular imaging, and a resource for those involved in the field. We begin by describing classical molecular imaging techniques together with their key strengths and limitations, after which we introduce some of the latest emerging imaging modalities. We provide an overview of the main classes of molecular imaging agents (i.e., small molecules, peptides, aptamers, engineered proteins, and nanoparticles) and cite examples of how molecular imaging is being applied in oncology, neuroscience, cardiology, gene therapy, cell tracking, and theranostics (therapy combined with diagnostics). A step-by-step guide to answering biological and/or clinical questions using the tools of molecular imaging is also provided. We conclude by discussing the grand challenges of the field, its future directions, and enormous potential for further impacting how we approach research and medicine.

Author(s):  
Benjamin P. Burke ◽  
Christopher Cawthorne ◽  
Stephen J. Archibald

Molecular imaging, where the location of molecules or nanoscale constructs can be tracked in the body to report on disease or biochemical processes, is rapidly expanding to include combined modality or multimodal imaging. No single imaging technique can offer the optimum combination of properties (e.g. resolution, sensitivity, cost, availability). The rapid technological advances in hardware to scan patients, and software to process and fuse images, are pushing the boundaries of novel medical imaging approaches, and hand-in-hand with this is the requirement for advanced and specific multimodal imaging agents. These agents can be detected using a selection from radioisotope, magnetic resonance and optical imaging, among others. Nanoparticles offer great scope in this area as they lend themselves, via facile modification procedures, to act as multifunctional constructs. They have relevance as therapeutics and drug delivery agents that can be tracked by molecular imaging techniques with the particular development of applications in optically guided surgery and as radiosensitizers. There has been a huge amount of research work to produce nanoconstructs for imaging, and the parameters for successful clinical translation and validation of therapeutic applications are now becoming much better understood. It is an exciting time of progress for these agents as their potential is closer to being realized with translation into the clinic. The coming 5–10 years will be critical, as we will see if the predicted improvement in clinical outcomes becomes a reality. Some of the latest advances in combination modality agents are selected and the progression pathway to clinical trials analysed. This article is part of the themed issue ‘Challenges for chemistry in molecular imaging’.


2020 ◽  
Vol 13 (8) ◽  
pp. 199
Author(s):  
Joseph Lau ◽  
Julie Rousseau ◽  
Daniel Kwon ◽  
François Bénard ◽  
Kuo-Shyan Lin

Kinins, bradykinin and kallidin are vasoactive peptides that signal through the bradykinin B1 and B2 receptors (B1R and B2R). B2R is constitutively expressed in healthy tissues and mediates responses such as vasodilation, fluid balance and retention, smooth muscle contraction, and algesia, while B1R is absent in normal tissues and is induced by tissue trauma or inflammation. B2R is activated by kinins, while B1R is activated by kinins that lack the C-terminal arginine residue. Perturbations of the kinin system have been implicated in inflammation, chronic pain, vasculopathy, neuropathy, obesity, diabetes, and cancer. In general, excess activation and signaling of the kinin system lead to a pro-inflammatory state. Depending on the disease context, agonism or antagonism of the bradykinin receptors have been considered as therapeutic options. In this review, we summarize molecular imaging agents targeting these G protein-coupled receptors, including optical and radioactive probes that have been used to interrogate B1R/B2R expression at the cellular and anatomical levels, respectively. Several of these preclinical agents, described herein, have the potential to guide therapeutic interventions for these receptors.


2016 ◽  
Vol 57 (10) ◽  
pp. 1583-1590 ◽  
Author(s):  
N. P. Withana ◽  
T. Saito ◽  
X. Ma ◽  
M. Garland ◽  
C. Liu ◽  
...  

2012 ◽  
Vol 13 (12) ◽  
pp. 16986-17005 ◽  
Author(s):  
Sung Kim ◽  
Mitsuru Hattori ◽  
Takeaki Ozawa

2017 ◽  
Vol 25 (3) ◽  
pp. 1163-1171 ◽  
Author(s):  
Victoria Calzada ◽  
María Moreno ◽  
Jessica Newton ◽  
Joel González ◽  
Marcelo Fernández ◽  
...  

Author(s):  
Eva M. Sevick-Muraca ◽  
Banghe Zhu ◽  
Barrett R. Harvey ◽  
Mary A. Hall ◽  
Kenneth L. Pinkston ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document